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ORIGINAL ARTICLE
Introduction: Surgical resection of an undiagnosed lung lesion may 
lead to unintentional removal of small-cell lung cancer (SCLC). The 
benefit of perioperative chemotherapy in resected SCLC or large-cell 
neuroendocrine carcinomas (LCNEC) is not clear.
Methods: This retrospective analysis included limited disease SCLC 
and LCNEC that had been surgically removed between 1979 and 2007 
at a single institution. Perioperative treatments were analyzed, and sur-
vival followed up. Log rank tests were used to compare overall survival.
Results: Among 74 patients who had a tumor resection, 45 received 
chemotherapy, four had preoperative radiotherapy, and 21 had post-
operative radiotherapy. Eleven patients were women. The median age 
was 64 in the surgery group and 58 in the surgery plus chemotherapy 
group, and four and 11 patients in these groups, respectively, had 
LCNEC. There were 10 node positive tumors and only two incomplete 
resections in the surgery group versus 27 node positive tumors and 
three incomplete resections in the surgery plus chemotherapy group. 
The median follow-up was shorter in the group with surgery alone: 
4.5 years (1.4–7) versus 5.8 years (0.6–19.6). Among the patients with 
a survival or a follow-up of at least 6 months, the median survival was 
2.3 and 6.1 years in the surgery (n = 20) and surgery plus chemother-
apy (n = 39) groups, respectively, such that the hazard ratio for death 
was 0.48 (95% confidence interval, 0.24–0.99, p = 0.04).
Conclusion: These results suggest that perioperative chemotherapy 
may be beneficial in patients with resected SCLC or LCNEC.
Key Words: Perioperative chemotherapy, Small-cell lung cancer, 
Surgery. 
(J of Thorac Oncol. 2012;7: 1179–1183)
Small-cell lung cancer (SCLC) represents approximately 15% of new cases of lung cancer diagnosed annually.1 It is 
an aggressive form of lung cancer that is associated in the vast 
majority, approximately 95%, of cases with cigarette smok-
ing.2 The most important prognostic factors are disease stage, 
performance status, and extent of weight loss. Elevated lactate 
dehydrogenase level is also associated with a poorer progno-
sis.3,4 At diagnosis, approximately 30% of patients with SCLC 
have limited disease (LD-SCLC).5,6 Combined modality treat-
ment involving chemotherapy and concurrent thoracic radio-
therapy is the current standard of treatment for LD-SCLC, and 
is followed by prophylactic cranial irradiation for all patients 
who achieve complete remission.7–10 The median survival is in 
the range 17 to 27 months, and the 5-year survival rate is 12% 
to 23%.5,8,11
SCLC is classically considered a contraindication for 
surgery because radiotherapy is at least equivalent in terms 
of local control, and the rate of resectability in SCLC patients 
is poor.12 However, some centers continue to support sur-
gery for very LD patients because experience suggests that 
it is possible to achieve a long-term survival in these selected 
patients.13,14 In daily practice, a small proportion of patients 
carrying resectable lung nodules receive a postoperative 
diagnosis of LD-SCLC. In screening programs, SCLC is 
diagnosed in 12.6% to 17.1% of patients undergoing nod-
ule resection.15,16 Among 12,620 cases of SCLC entered in 
the International Association for the Study of Lung Cancer 
(IASLC) data set used for the 7th edition of the classification 
of SCLC, surgically treated SCLC represented only 1.3% of 
all fully staged resected cases in the database and only 2.8% 
of all SCLC cases.17 Some authors have reported 5-year sur-
vival rates of 30% to 40% for patients who underwent surgical 
resection before the histological diagnosis of SCLC and who 
were also given chemotherapy, chest radiotherapy, or both.18,19 
In the International Association for the Study of Lung Cancer 
(IASLC) data set (n = 339), the observed 5-year survival rate 
was 40% to 56% for patients with stage IIB disease or less, 
who were initially treated by surgical resection, and 12 % for 
stage IIIA.17 The rate of adjuvant treatment in this data set of 
patients treated mostly between 1990 and 2000 is unknown. 
In the National Cancer Institute Surveillance Epidemiology 
and End Results, 247 patients underwent surgical resection for 
SCLC between 1988 and 2004.20 Of 205 patients with stage 
I SCLC who required only lobectomy, the 5-year survival 
rate was 50.3%. Surveillance Epidemiology and End Result 
does not provide chemotherapy details but it is assumed that 
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most, if not all, of these patients received systemic therapy. 
Despite these reports, the role of surgery has not been estab-
lished and the role of adjuvant treatment in resected patients 
is unknown.21
Large-cell neuroendocrine carcinoma (LCNEC) is a 
subgroup of large-cell carcinoma and is a type of lung can-
cer showing neuroendocrine characteristics similar to that of 
SCLC.22 A small number of studies suggest that after com-
plete resection of pulmonary LCNEC, an adjuvant treatment 
combining etoposide and a platinum compound could be of 
value, but this needs to be confirmed.23,24
In a retrospective study, we assessed the role of che-
motherapy before or after a local treatment that in all cases 
included surgery, comparing the survival of two groups of 
patients diagnosed with LD-SCLC or early LCNEC: the first 
group was treated by surgery and chemotherapy combined, 
and the second by surgery alone.
MATERIALS AND METHODS
This retrospective study included LD-SCLC (according 
to the staging system of the Veterans’ Administration Lung 
Study Group) and early LCNEC surgically removed between 
1979 and 2007 at the Surgical Centre Marie Lannelongue. We 
collected data on the patients’ characteristics (sex, age, and 
smoking status), the type of neuroendocrine tumor (SCLC 
or LCNEC), stage (according to the 6th edition of the tumor, 
node, metastasis (TNM) staging system based on the crite-
ria established by the American Joint Committee for Cancer 
and IASLC), the type of surgery and its extent, the periopera-
tive treatment (either systemic treatment or radiotherapy) and 
the outcome (recurrence, metastatic sites, second tumor, and 
cause of death).
Tumors were classified according to the World Health 
Organization classification.25,26 LCNEC fulfilled the follow-
ing criteria: neuroendocrine morphology, mitotic rate greater 
than 10 per 10 high-power field, necrosis, cytologic features 
of non–small-cell lung cancer (NSCLC), and positive immu-
nohistochemical staining for one or more neuroendocrine 
markers. The neuroendocrine markers used were CD56, chro-
mogranin, and synaptophysin. NSCLCs showing neuroendo-
crine differentiation (NSCLC-NE) were not included in our 
series because the relevance of immunohistochemichal neuro-
endocrine differentiation in NSCLC that does not show neu-
roendocrine morphology is controversial.27
Statistical Analysis
The χ2 test, Fisher’s exact test, t test, and the Wilcoxon 
test were used as appropriate to compare the patients who 
received or did not receive adjuvant treatment. Overall sur-
vival (OS) was calculated as the interval from the date of sur-
gery until death from any cause or until the date of the last 
follow-up. Follow-up was assessed by the reverse Kaplan-
Meier method.28 OS curves were estimated by the Kaplan-
Meier method and were compared with the log rank test. All 
p values were two-sided and p values of less than 0.05 were 
considered significant. Data were analyzed using SAS statisti-
cal software (SAS Institute, Cary, NC).
RESULTS
We identified 75 patients with resected SCLC and 
LCNEC: 42 patients had no preoperative pathological diagno-
sis (Table 1). One patient was excluded because of a definitive 
TABLE 1.  Baseline Characteristics of the Patients
Characteristic
Surgery  
Alone  
(n = 29)
Surgery Plus 
Perioperative 
Chemotherapy  
(n = 45) p Value
Age at diagnosis  
median (range, year) 64 (49–78) 58 (33–78) 0.12
Male n (%) 25 (86) 38 (84) 0.87
Smoking status: n (%) 0.08
 Never  3 (10) 0 (0)
 Current 16 (55) 32 (71)
 Former 10 (35) 13 (29)
Number of packets  
median (range)
40 (6–100) 40 (10–80) 0.71
Preoperative  
diagnosis n (%) 0.002c
 Unknown 22 (76) 20 (45)
 SCLC  4 (14) 14 (31)
 LCNEC  2 (7) 6 (13)
 Other  1 (3)a 5 (11)b
Clinical stage n (%) 0.36d
 Stage I 15 (52) 19 (42)
 Stage II  6 (21) 13 (29)
 Stage III+IV  3 (10) 10 (22)
 Unknown  5 (17) 3 (7)
pTumor category n (%) 0.63e
 T1  5 (17) 9 (20)
 T2 15 (52) 20 (44)
 T3  2 (6) 11 (24)
 T4  3 (10) 1 (2)
Unknown  4 (15) 4 (10)
pNodal status n (%) 0.05f
 N- 15 (52) 15 (33)
 N+ 10 (34) 27 (60)
 Unknown  4 (14) 3 (7)
Type of surgery n (%) 1.00g
 Lobectomy 19 (66) 26 (58)
 Pneumonectomy  8 (28) 13 (29)
 Bi-lobectomy  1 (3) 5 (11)
 Segmentectomy  1 (3) 1 (2)
Type of resection n (%) 0.01
 Complete resection 27 (93) 42 (93)
 Incomplete resection  2 (7) 3 (7)
Postoperative  
diagnosis n (%) 0.38
 SCLC 25 (86) 34 (76)
 LCNEC  4 (14) 11 (24)
SCLC, small-cell lung cancer; LCNEC, large-cell neuroendocrine carcinomas.
aAtypical carcinoid.
bNon–small-cell lung cancer n = 2, undifferentiated carcinoma n = 3.
cUnknown vs. SCLC + LCNEC vs. other.
dStage I vs. stage II vs. stage III+IV.
eT1 vs. T2 vs. T3-4.
fN– vs. N+.
gPneumonectomy vs. other. 
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diagnosis of atypical carcinoid so that the analysis included 
the 74 remaining patients. Forty-five patients underwent 
surgery combined with perioperative chemotherapy, and 29 
underwent surgery alone. Patients’ baseline characteristics are 
shown in Table 1. Among the 45 patients in the surgery-plus-
perioperative chemotherapy group, 10 received a preopera-
tive treatment with chemotherapy alone (n = 6), concurrent 
chemoradiotherapy (n = 3), or radiotherapy alone (n = 1). In 
the same group, 37 patients received postoperative treatment 
with chemotherapy alone (n = 16), concurrent chemoradio-
therapy (n = 19), or radiotherapy alone (n = 2). Three patients 
received both pre- and postoperative treatment: two had preop-
erative chemotherapy with either postoperative radiotherapy 
or concurrent chemoradiotherapy, and one had preoperative 
radiotherapy and postoperative chemotherapy. Most of the 
systemic therapies involved platinum-based drugs combined 
with either etoposide (62%) or another agent (13%; cyclo-
phosphamide, doxorubicin, metotrexate, or ifosfamide). The 
remaining 25% patients received a platinum-free regimen. 
Seven patients received prophylactic cranial irradiation, all of 
them in the surgery-plus-perioperative chemotherapy group.
The patients in the surgery-alone group were resected 
earlier during the study (median year of surgery 1998, range, 
1979–2007) compared with the chemotherapy group (median 
year of surgery 2001, range, 1980–2007). Stage was unknown 
in eight cases (10.8%); 51% cases (n = 34) were at stage I, 29% 
at (n = 19) stage II, and 20% at (n = 13) stage III–IV (Table 1). 
Clinical TNM (cTNM), in patients who did not receive preop-
erative chemotherapy, was compared with pathological TNM 
(pTNM). Seven values were missing, and 59 cases were assess-
able. In 30 patients (51%), there was no TNM change. The 
T-factor differed in 12 cases (20%) with underestimation of the 
cT versus pT in nine cases. The N-factor differed in 21 cases 
(36%) with underestimation of the cN versus pN in 17 cases.
Only patients whose follow-up was 6 months or more 
(n = 59) were included in the survival analysis, such that 
patients who experienced postoperative death or rapidly 
growing metastatic disease refractory to chemotherapy were 
excluded. Thus, 15 patients (nine in the group without chemo-
therapy) were excluded from the survival analysis: (1) three 
patients were alive at the time of the last follow-up visit but the 
follow-up was shorter than 6 months (one in the group with-
out chemotherapy and two in the group with chemotherapy), 
(2) four patients died within 1 month of surgery (considered to 
be postoperative death), including one patient who died from 
cancer (all in the group without chemotherapy), and (3) eight 
patients died between 1 and 6 months after surgery (four in the 
group without chemotherapy, including one death from can-
cer, two deaths from other causes, and one death of unknown 
cause; and four in the group with chemotherapy, including 
three deaths from cancer and one death of unknown cause).
Among the 59 patients with a survival and a follow-up 
of at least 6 months, the median duration of follow-up was 
5.8 years (range, 0.6–19.6 years) and 33 died during fol-
low-up. Follow-up was shorter for the surgery-alone group 
(4.5 years; range, 1.4–7.0 years) than for the surgery-plus-
perioperative chemotherapy group (5.8 years; range, 0.6–19.6 
years). The median survival was 2.3 years (1.4–7.0) for the 
surgery-alone group and 6.1 years (0.6–19.6) for the group 
with perioperative chemotherapy (Fig. 1). The hazard ratio 
(HR) for death was 0.48 (95% confidence interval [CI], 0.24–
0.99; p = 0.04) for the perioperative chemotherapy group 
compared with the surgery-alone group. The OS rates at 1, 
2, and 3 years were 92%, 79%, and 59%, respectively in the 
perioperative chemotherapy group, and 85%, 54%, and 48% 
in the surgery-alone group, respectively.
A sensitivity analysis was performed by censoring 
follow-up at 3 years (Fig. 2). Thus, a patient who died 3.5 
years after surgery was considered to be alive in this analysis. 
Similarly, a patient still alive after 5 years of follow-up was 
considered to be living with only 3 years of follow-up. The 
objective of this analysis was to mitigate the imbalance in the 
duration of follow-up between the two treatment groups: cen-
soring follow-up at 3 years contributes to standardizing the 
follow-up between the two treatment groups (median follow-
up was 3 years for each group). The median survival was not 
reached by 3 years in the group with chemotherapy, because 
less than 50% of the patients died. For the group without che-
motherapy, the median survival was 2.3 years. The HR for 
FIGURE 2. Overall survival and sensitivity analysis—censor-
ing the follow-up after 3 years.
FIGURE 1. Overall survival according to treatment group: 
surgery (S) and surgery plus chemotherapy (S + C).
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death was 0.58 (95% CI, 0.26–1.31; p = 0.18) for the group 
that received chemotherapy compared with the group with 
surgery alone. The OS rates at 1, 2, and 3 years were 85%, 
54%, and 48% in the surgery-alone group and 92%, 79%, and 
59% in the surgery-plus-perioperative chemotherapy group. 
We evaluated the impact of prophylactic cranial irradiation 
(PCI) on survival result. The sensitivity analysis for OS was 
performed for the population without the seven patients who 
received PCI (n = 52). The HR for death was 0.60 (95% CI, 
0.26–1.39; p = 0.22) for the group that received chemotherapy 
compared with the group with surgery alone.
We used univariate analysis to study the prognostic 
value of three factors: the type of surgery (complete versus 
incomplete), the node status of the patient (pN- versus pN+), 
and type of cancer (SCLC versus LCNEC). As for the survival 
analysis, we restricted this analysis to the 59 patients whose 
follow-up was 6 months or longer. None of these three vari-
ables were significantly related to OS.
DISCUSSION
We report the first retrospective study to compare the 
benefit of the use of perioperative chemotherapy for survival 
in patients with resected SCLC and LCNEC. Our findings 
suggest that treatment involving surgery plus perioperative 
chemotherapy was associated with a significantly longer OS 
than surgery alone (6.1 years and 2.3 years, respectively) and 
the HR for death was 0.48 (95% CI, 0.24–0.99; p = 0.04). 
However, follow-up was shorter for patients in the group 
without chemotherapy (4.5 versus 5.8), and this may intro-
duce a bias in the analysis. We therefore conducted a sensitiv-
ity analysis by censoring the follow-up of patients at 3 years. 
This analysis in a limited population showed a nonsignificant 
improvement of OS, but the tendency for a benefit was still 
observed (HR: 0.58 (95% CI 0.26; 1.31, p = 0.18).
The evidence for the benefits of surgery in LD-SCLC 
is poor. Three studies suggest that surgical resection 
plus chemotherapy in LD-SCLC is of more benefit than 
nonsurgical management.13,29,30 A Japanese retrospective 
study investigated 91 patients who had undergone pulmonary 
resection for SCLC.30 The subgroup of 40 patients with 
p-stage IA–IIB, who received perioperative chemotherapy 
was compared with nine patients treated by surgery alone. The 
5-year probability of survival for patients with perioperative 
chemotherapy was 54.9% as compared with 22.2% for 
patients without chemotherapy (p = 0.015). The poor survival 
rate of the surgery-alone group may have been because of an 
excess of comorbidities: when the authors censored patients 
whose cause of death was other than SCLC, the difference 
in the 5-year probability of survival did not persist. Lucchi 
et al. reported the OS of 127 patients who underwent radical 
resection of SCLC.30 The 20 patients who were treated with 
surgery alone died within 2 years whereas the 5-year survival 
rates were 32% for the 92 patients treated with surgery and 
adjuvant chemotherapy, and 13% for the 15 patients treated 
with preoperative chemotherapy alone or in combination with 
adjuvant chemotherapy. Unfortunately, no formal comparison 
was reported of the survival in the arms with surgery alone and 
surgery plus perioperative chemotherapy. Moreover, the poor 
survival of the surgery arm can be explained by the higher 
rate of node-positive patients: 75% versus 48% in the surgery 
and adjuvant chemotherapy arm, respectively. In our study, 
the benefit of adjuvant chemotherapy was evidenced despite a 
higher rate of node-positive patients in the chemotherapy arm.
In most published studies, the survival benefit associated 
with surgery is limited to stage I and II disease.18,19,31,32,17,20,30 
This is concordant with our observations. In our series, 80% 
of patients in the group surgery plus perioperative treatment 
(chemotherapy, radiotherapy, or both) were stage I or II. In 
various series of LD-SCLC managed by surgery plus peri-
operative chemotherapy, the 5-year OS ranged from 32% 
to 60%.13,29,30,32,33 It may be difficult to compare these series 
because the rate of N2 disease or complete resection may dif-
fer among them. Timelines may also be of importance; in our 
cohort study, 82.5% of patients were operated between 1990 
and 2007 with more than half after 2000. In recent years, the 
rate of lobectomy has increased, the use of platinum-based 
adjuvant chemotherapy has become more systematic, and 
workup is more extensive. These various factors may together 
explain the favorable median survival in our patients (6.1 
years, Fig. 1). The use of adjuvant mediastinal radiotherapy 
may improve OS, as is the case for patients treated with com-
bined chemoradiotherapy.7,10,34 The use of PCI did not affect 
the results of our sensitivity analysis because results were 
similar if patients who received PCI were excluded from the 
analysis.
We are aware that our study has limitations that make 
it difficult to interpret the results. We have no data on per-
formance status (a major prognostic factor) or lactate dehy-
drogenase. The TNM-staging system according to the criteria 
established by the American Joint Committee for Cancer and 
IASLC is more accurate for classifying SCLC.17,35 It has been 
recommended since 2002 but we began our retrospective 
study in 1979. We therefore had to use the staging system 
for SCLC introduced by the Veterans’ Administration Lung 
Study Group as an inclusion criterion to be consistent for all 
our patients. Preoperative workup was probably suboptimal, 
given the long inclusion period. This may explain the underes-
timation of the cTNM relative to the pTNM, as also observed 
by Inoue et al.30 Improved imaging (including computed 
tomography scanning) and metabolic assessment (positron 
emission tomography scanning) may allow better selection 
of patients eligible for surgery. We do not have sufficient 
data concerning the surgery group to analyze and explain the 
decision for not using perioperative treatment. Of note, more 
patients had a node involvement in the chemotherapy group, 
indicating that physicians may have offered chemotherapy to 
patients with more advanced disease. No definitive conclu-
sion can be made concerning this issue because of the small 
population examined in this study, its retrospective nature, 
the difference in follow-up between the two groups, and the 
heterogeneity of the combined treatments. Nevertheless, this 
study raises a very important question regarding the ben-
efit of perioperative treatment  for patients with surgically 
resected LD-SCLC.
Histology (SCLC versus LCNEC) was not a prognostic 
factor in our study. Only 15 patients with LCNEC were included 
in the cohort, of which 11 received adjuvant chemotherapy. In 
a retrospective cohort of 83 patients with resected LCNEC, 
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Rossi et al.24 reported a better survival for the 38 patients who 
received adjuvant chemotherapy. Interestingly, the multivariate 
analyses showed a better outcome for patients receiving 
a SCLC-targeting regimen (platinum-etoposide) than a 
NSCLC-targeting regimen (response rate = 15.5 [5.0–47.8], 
p = 0.0001). A Japanese study reported a 2-year survival of 
88% (68–109) for 15 consecutive patients treated by complete 
resection followed by platinum-etoposide chemotherapy but 
only 65% (45–84) in a historical cohort of 23 patients treated 
by surgery alone.36 These results are consistent with the 
benefit reported in our study.
Our results suggest that surgical resection combined 
with adjuvant or neoadjuvant chemotherapy may be an appro-
priate option for patients with early disease SCLC or LCNEC. 
A prospective trial to address this issue would be useful, but 
may be difficult to run in this setting.
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